Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 4/20 | 0.64 |
| ▸ | TERT | O14746 | 2/20 | 0.61 |
| ▸ | DTYMK | P23919 | 4/20 | 0.60 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.53 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.53 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | RNASEL | Q05823 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29395274 | 1.00 | F2 (0.64) | F2TERTDTYMKP2RY2P2RY4 | |
| SCHEMBL29959672 | 1.00 | F2 (0.64) | F2TERTDTYMKP2RY2P2RY4 | |
| SCHEMBL29689844 | 1.00 | F2 (0.64) | F2TERTDTYMKP2RY2P2RY4 | |
| SCHEMBL29716657 | 1.00 | F2 (0.64) | F2TERTDTYMKP2RY2P2RY4 | |
| SCHEMBL32665846 | 1.00 | F2 (0.64) | F2TERTDTYMKP2RY2P2RY4 | |
| SCHEMBL29986652 | 1.00 | F2 (0.64) | F2TERTDTYMKP2RY2P2RY4 | |
| SCHEMBL14174120 | 1.00 | F2 (0.64) | F2TERTDTYMKP2RY2P2RY4 | |
| SCHEMBL29690373 | 1.00 | F2 (0.64) | F2TERTDTYMKP2RY2P2RY4 | |
| SCHEMBL14184947 | 1.00 | F2 (0.64) | F2TERTDTYMKP2RY2P2RY4 | |
| SCHEMBL29387073 | 1.00 | F2 (0.64) | F2TERTDTYMKP2RY2P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 265 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731257-A1 | CONJUGATES OF SAPONIN AND ANTISENSE OLIGONUCLEOTIDES FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | Sapreme Technologies B.V. (NL) | 2026-04-29 | — | — | EP | claimed |
| EP-4731261-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | Sapreme Technologies B.V. (NL) | 2026-04-29 | — | — | EP | claimed |
| EP-4719478-A1 | IMPROVED TREATMENT REGIMENS FOR THERAPEUTIC EFFECTOR COMPONENTS THAT ACT VIA AN INTRACELLULAR MOLECULAR TARGET | Sapreme Technologies B.V. (NL) | 2026-04-08 | — | — | EP | claimed |
| WO-2024261044-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | SAPREME TECHNOLOGIES B.V. (NL) | 2024-12-26 | — | — | WO | claimed |
| WO-2024261042-A1 | CONJUGATES OF SAPONIN AND ANTISENSE OLIGONUCLEOTIDES FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | SAPREME TECHNOLOGIES B.V. (NL) | 2024-12-26 | — | — | WO | claimed |
| WO-2024246051-A1 | IMPROVED TREATMENT REGIMENS FOR THERAPEUTIC EFFECTOR COMPONENTS THAT ACT VIA AN INTRACELLULAR MOLECULAR TARGET | SAPREME TECHNOLOGIES B.V. (NL) | 2024-12-05 | — | — | WO | claimed |
| US-20240207409-A1 | ORAL DELIVERY OF OLIGONUCLEOTIDES | CIVI BIOPHARMA INC (US) | 2024-06-27 | — | — | US | claimed |
| CN-118103340-A | Method for manufacturing medical injection device and medical injection device manufactured by same | 斯特瓦纳托集团有限公司 | 2024-05-28 | — | — | CN | claimed |
| EP-4326329-A1 | ORAL DELIVERY OF OLIGONUCLEOTIDES | Civi Biopharma, Inc. (US) | 2024-02-28 | — | — | EP | claimed |
| US-20230210852-A1 | METHODS OF TREATING CANCER IN PATIENTS WITH AN ANOMALOUS KRAS GENE OR DELETIONS WITHIN CHROMOSOME 9 | MEDIC LIFE SCIENCES, INC. | 2023-07-06 | — | — | US | claimed |
| EP-4157465-A2 | METHODS OF TREATING CANCER IN PATIENTS WITH AN ANOMALOUS KRAS GENE OR DELETIONS WITHIN CHROMOSOME 9 | Syros Pharmaceuticals, Inc. (US) | 2023-04-05 | — | — | EP | claimed |
| US-20220380761-A1 | ORAL DELIVERY OF OLIGONUCLEOTIDES | CIVI BIOPHARMA, INC. (US) | 2022-12-01 | — | — | US | claimed |
| WO-2022226217-A1 | ORAL DELIVERY OF OLIGONUCLEOTIDES | CIVI BIOPHARMA, INC. (US) | 2022-10-27 | — | — | WO | claimed |
| EP-4051282-A1 | METHODS OF TREATING CANCER IN BIOMARKER-IDENTIFIED PATIENTS WITH INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | Syros Pharmaceuticals, Inc. (US) | 2022-09-07 | — | — | EP | claimed |
| US-20260130893-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4735445-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4735453-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-3972695-A1 | SUBSTITUTED EXO-METHYLENE-OXINDOLES WHICH ARE HPK1/MAP4K1 INHIBITORS | Gilead Sciences, Inc. (US) | 2022-03-30 | — | — | EP | disclosed |
| CN-114245807-A | FLT3L-FC fusion proteins and methods of use | 吉利德科学公司 | 2022-03-25 | — | — | CN | disclosed |
| US-20220049021-A1 | FLT3L-Fc FUSION PROTEINS AND METHODS OF USE | GILEAD SCIENCES, INC. | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210852-A1 | METHODS OF TREATING CANCER IN PATIENTS WITH AN ANOMALOUS KRAS GENE OR DELETIONS WITHIN CHROMOSOME 9 | CDKL5, KRAS, CDK9 | F2 4029/4885TERT 761/4885DTYMK 526/4885 |
| US-20240207409-A1 | ORAL DELIVERY OF OLIGONUCLEOTIDES | RNGTT, RNMT, SRRT | F2 4885/4885TERT 3199/4885DTYMK 437/4885 |
| US-20260130893-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | F2 4873/4885TERT 216/4885DTYMK 1296/4885 |
| US-20220380761-A1 | ORAL DELIVERY OF OLIGONUCLEOTIDES | RNGTT, RNMT, SRRT | F2 4885/4885TERT 3199/4885DTYMK 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.